| Literature DB >> 31906096 |
Oliver D John1,2, Peter Mouatt3, Marwan E Majzoub4, Torsten Thomas4, Sunil K Panchal1, Lindsay Brown1,2.
Abstract
Metabolic syndrome is a cluster of disorders that increase the risk of cardiovascular disease and diabetes. This study has investigated the responses to rind of yellow mangosteen (Garcinia dulcis), usually discarded as waste, in a rat model of human metabolic syndrome. The rind contains higher concentrations of phytochemicals (such as garcinol, morelloflavone and citric acid) than the pulp. Male Wistar rats aged 8-9 weeks were fed either corn starch diet or high-carbohydrate, high-fat diet for 16 weeks, which were supplemented with 5% freeze-dried G. dulcis fruit rind powder during the last 8 weeks. We characterised metabolic, cardiovascular, liver and gut microbiota parameters. High-carbohydrate, high-fat diet-fed rats developed abdominal obesity, hypertension, increased left ventricular diastolic stiffness, decreased glucose tolerance, fatty liver and reduced Bacteroidia with increased Clostridia in the colonic microbiota. G. dulcis fruit rind powder attenuated these changes, improved cardiovascular and liver structure and function, and attenuated changes in colonic microbiota. G. dulcis fruit rind powder may be effective in metabolic syndrome by appetite suppression, inhibition of inflammatory processes and increased fat metabolism, possibly related to changes in the colonic microbiota. Hence, we propose the use of G. dulcis fruit rind as a functional food to ameliorate symptoms of metabolic syndrome.Entities:
Keywords: Garcinia dulcis; citric acid; garcinol; metabolic syndrome; microbiota; morelloflavone
Mesh:
Substances:
Year: 2019 PMID: 31906096 PMCID: PMC6981489 DOI: 10.3390/ijms21010272
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Whole Garcinia dulcis fruit, (B) Garcinia dulcis rind and pulp and (C) high-performance liquid chromatography profile at 210 nm of Garcinia dulcis pulp, rind and seed.
Effects of Garcinia dulcis rind on physiological, metabolic and cardiovascular parameters.
| Variables | C | CGD | H | HGD | |||
|---|---|---|---|---|---|---|---|
| Diet | Treatment | Interaction | |||||
|
| |||||||
| Initial body weight, g | 338 ± 0.9a | 339 ± 0.7a | 337 ± 0.7a | 337 ± 0.7a | 0.35 | 0.46 | 0.32 |
| 8-week body weight, g | 355 ± 6.6b | 362 ± 7.0b | 423 ± 6.4a | 422 ± 10a | <0.0001 | 0.75 | 0.61 |
| 16-week body weight, g | 404 ± 8b | 306 ± 6d | 508 ± 11a | 362 ± 10c | <0.0001 | <0.0001 | 0.011 |
| Food intake, g/day | 41.2 ± 2.3a | 26.3 ± 2.3b | 27.0 ± 2.5b | 20.1 ± 1.9b | 0.0001 | <0.0001 | 0.10 |
| Water intake, g/day | 23.6 ± 2.6a | 28.7 ± 2.9a | 28.6 ± 6.0a | 37.6 ± 4.5a | 0.10 | 0.09 | 0.64 |
| Garcinol intake, mg/kg/day | - | 210 ± 7 | - | 130 ± 8 | - | - | - |
| Citric acid intake, mg/kg/day | - | 780 ± 27 | - | 480 ± 23 | - | - | - |
| Morelloflavone intake, mg/kg/day | - | 7.3 ± 0.2 | - | 5.4 ± 0.1 | - | - | - |
| Energy intake, kJ/day | 462 ± 28b | 318 ± 10c | 603 ± 52a | 501 ± 12b | <0.0001 | 0.0002 | 0.49 |
| Feed efficiency (8–16 weeks), g/kJ | 0.10 ± 0.01a | −0.18 ± 0.02b | 0.15 ± 0.02a | −0.11 ± 0.02b | 0.002 | <0.0001 | 0.58 |
| Body weight gained (8–16 weeks), % | 13.7 ± 1.0b | −15.4 ± 0.8c | 20.1 ± 2.8a | −13.0 ± 2.2c | 0.024 | <0.0001 | 0.29 |
| Abdominal circumference 8 weeks, cm | 16.1 ± 0.2b | 16.6 ± 0.3b | 19.8 ± 0.5a | 20.4 ± 0.5a | <0.0001 | 0.18 | 0.91 |
| Abdominal circumference 16 weeks, cm | 18.4 ± 0.4b | 15.0 ± 0.2d | 22.6 ± 0.4a | 16.8 ± 0.4c | <0.0001 | <0.0001 | 0.001 |
| Whole body lean mass 8 weeks, g | 283 ± 12a | 300 ± 4a | 310 ± 6a | 302 ± 5a | 0.047 | 0.56 | 0.09 |
| Whole body lean mass 16 weeks, g | 289 ± 10a | 267 ± 5a | 297 ± 8a | 265 ± 13a | 0.71 | 0.007 | 0.62 |
| Whole body fat mass 8 weeks, g | 57 ± 5b | 51 ± 8b | 94 ± 8a | 105 ± 19a | 0.002 | 0.86 | 0.55 |
| Whole body fat mass 16 weeks, g | 96 ± 9b | 23 ± 3c | 203 ± 12a | 84 ± 6b | <0.0001 | <0.0001 | 0.012 |
| Bone mineral content 8 weeks, g | 11.0 ± 0.6a | 10.6 ± 0.5a | 11.8 ± 0.3a | 12.0 ± 0.6a | 0.025 | 0.83 | 0.81 |
| Bone mineral content 16 weeks, g | 12.4 ± 0.5b | 10.0 ± 0.2c | 16.1 ± 0.5a | 11.8 ± 0.3b | <0.0001 | <0.0001 | 0.019 |
| Bone mineral density 8 weeks, g/cm2 | 0.163 ± 0.004a | 0.160 ± 0.005a | 0.168 ± 0.004a | 0.164 ± 0.002a | 0.26 | 0.39 | 0.87 |
| Bone mineral density 16 weeks, g/cm2 | 0.173 ± 0.004b | 0.165 ± 0.003b | 0.185 ± 0.003a | 0.162 ± 0.003b | <0.0001 | 0.18 | 0.027 |
| Body mass index 16 weeks, g/cm2 | 0.63 ± 0.02b | 0.54 ± 0.02c | 0.77 ± 0.02a | 0.60 ± 0.02b | <0.0001 | <0.0001 | 0.052 |
| Retroperitoneal fat, mg/mm tibial length | 255 ± 22b | 71 ± 7d | 497 ± 33a | 160 ± 18c | <0.0001 | <0.0001 | 0.001 |
| Epididymal fat, mg/mm tibial length | 101 ± 16b | 39 ± 6c | 165 ± 18a | 49 ± 5c | 0.006 | <0.0001 | 0.040 |
| Omental fat, mg/mm tibial length | 159 ± 14b | 66 ± 4d | 260 ± 11a | 115 ± 8c | <0.0001 | <0.0001 | 0.015 |
| Total abdominal fat, mg/mm tibial length | 515 ± 45b | 176 ± 13d | 951 ± 49a | 325 ± 29c | <0.0001 | <0.0001 | 0.001 |
| Visceral adiposity index, % | 5.84 ± 0.43b | 2.60 ± 0.20d | 8.65 ± 0.39a | 4.24 ± 0.37c | <0.0001 | <0.0001 | 0.11 |
| Kidney wet weight, mg/mm tibial length | 50.2 ± 1.2b | 40.7 ± 1.2c | 56.0 ± 1.6a | 47.1 ± 1.3b | <0.0001 | <0.0001 | 0.82 |
| Heat production 16 weeks, kcal/hour | 4.06 ± 0.40a | 2.06 ± 0.14b | 4.20 ± 0.49a | 3.59 ± 0.31a | 0.029 | 0.003 | 0.06 |
| Heat production area under the curve 16 weeks, (kcal/hour) × minutes | 2878 ± 212ab | 1419 ± 76c | 3193 ± 97a | 2500 ± 201b | 0.002 | <0.0001 | 0.053 |
| Respiratory exchange ratio 16 weeks | 0.973 ± 0.010a | 0.986 ± 0.024a | 0.886 ± 0.017b | 0.898 ± 0.037b | 0.012 | 0.66 | 0.99 |
| Respiratory exchange ratio area under the curve 16 weeks | 700 ± 9a | 707 ± 16a | 618 ± 15b | 631 ± 18b | 0.0005 | 0.48 | 0.82 |
| Mean liver fat vacuoles area, µm2 | 14.1 ± 0.8c | 9.8 ± 0.5c | 150.1 ± 13.6a | 73.0 ± 8.8b | <0.0001 | <0.0001 | <0.0001 |
| Mean retroperitoneal adipocyte area, µm2 | 4299 ± 120b | 2290 ± 67c | 9966 ± 195a | 4115 ± 326b | <0.0001 | <0.0001 | <0.0001 |
|
| |||||||
| Plasma alanine transaminase activity, U/L | 28.4 ± 4.0b | 33.8 ± 2.7a | 42.3 ± 5.0a | 39.1 ± 5.1a | 0.025 | 0.89 | 0.28 |
| Plasma aspartate transaminase activity, U/L | 83.0 ± 8.0b | 86.5 ± 9.0b | 173.9 ± 24.0a | 91.4 ± 6.6b | 0.001 | 0.007 | 0.003 |
| Plasma total cholesterol, mmol/L | 1.37 ± 0.07a | 0.95 ± 0.06b | 1.66 ± 0.10a | 1.50 ± 0.12a | <0.0001 | 0.003 | 0.16 |
| Plasma triglycerides, mmol/L | 0.45 ± 0.05b | 0.25± 0.02b | 1.15 ± 0.17a | 0.35 ± 0.08b | 0.0008 | <0.0001 | 0.009 |
| Plasma non-esterified fatty acids, mmol/L | 0.87 ± 0.18b | 0.35 ± 0.04c | 3.25 ± 0.17a | 0.80 ± 0.16b | <0.0001 | <0.0001 | <0.0001 |
| Basal blood glucose 8 weeks, mmol/L | 2.4 ± 0.1b | 2.3 ± 0.1b | 3.1 ± 0.1a | 3.0 ± 0.1a | <0.0001 | 0.33 | 1.0 |
| Basal blood glucose 16 weeks, mmol/L | 2.6 ± 0.1ab | 2.4 ± 0.2b | 3.0 ± 0.1a | 2.8 ± 0.1ab | 0.003 | 0.13 | 1.0 |
| Blood glucose area under the curve 8 weeks, mmol/L × minutes | 488 ± 9b | 494 ± 11b | 596 ± 13a | 585 ± 7a | <0.0001 | 0.82 | 0.43 |
| Blood glucose area under the curve 16 weeks, mmol/L × minutes | 466 ± 17c | 401 ± 17d | 602 ± 24a | 544 ± 19b | <0.0001 | 0.003 | 0.86 |
| Insulin response area under the curve 8 weeks, mmol/L × minutes | 175 ± 23b | 200 ± 34b | 416 ± 55a | 413 ± 12a | <0.0001 | 0.78 | 0.72 |
| Insulin response area under the curve 16 weeks, mmol/L × minutes | 149 ± 19c | 154 ± 22c | 373 ± 24a | 281 ± 21b | <0.0001 | 0.028 | 0.017 |
| Liver wet weight, mg/mm tibial length | 231 ± 8b | 212 ± 7b | 358 ± 15a | 341 ± 13a | <0.0001 | 0.14 | 0.91 |
| Liver glycogen, mg/g | 12.9 ± 0.4a | 4.8 ± 0.5c | 13.9 ± 0.4a | 8.4 ± 1.2b | 0.002 | <0.0001 | 0.08 |
| Plasma catalase activity, kU/L | 39.0 ± 4.7b | 45.6 ± 6.0ab | 56.9 ± 8.1a | 56.9 ± 8.8a | 0.030 | 0.69 | 0.69 |
| Plasma C-reactive protein, µg/mL | 432 ± 5b | 355 ± 22c | 506 ± 8a | 376 ± 19c | 0.034 | 0.0002 | 0.19 |
| Faecal lipid content, mg/g | 21.8 ± 1.5b | 8.1 ± 0.4c | 43.3 ± 1.6a | 42.1 ± 5.4a | <0.0001 | 0.015 | 0.039 |
|
| |||||||
| Systolic blood pressure 8 weeks, mmHg | 116 ± 3b | 121 ± 2b | 133 ± 4a | 132 ± 3a | <0.0001 | 0.45 | 0.24 |
| Systolic blood pressure 16 weeks, mmHg | 117 ± 2bc | 111 ± 3c | 135 ± 2a | 121 ± 5b | <0.0001 | 0.006 | 0.43 |
| Left ventricle + septum wet weight, mg/mm tibial length | 23.3 ± 1.4a | 18.9 ± 0.7a | 22.8 ± 1.4a | 18.5 ± 0.8a | 0.72 | 0.0005 | 0.99 |
| Right ventricle wet weight, mg/mm tibial length | 4.1 ± 0.2ab | 3.6 ± 0.3b | 4.7 ± 0.2a | 4.0 ± 0.3ab | 0.027 | 0.059 | 0.74 |
| Left ventricular diastolic stiffness (κ) | 21.6 ± 0.2b | 21.9 ± 0.9b | 26.7 ± 0.6a | 22.5 ± 0.6b | <0.0001 | 0.004 | 0.001 |
Values are expressed as mean ± SEM, n = 8–12. Means with different superscripts (a, b, c or d) differ, p < 0.05. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats supplemented with 5% Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats supplemented with 5% Garcinia dulcis rind powder.
Figure 2(A) Weekly body weight of C, CGD, H and HGD rats; dotted line signifies when treatment started for CGD and HGD rats, (B) Distribution of retroperitoneal adipocyte sizes. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats supplemented with 5% Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats supplemented with 5% Garcinia dulcis rind powder.
Figure 3Haematoxylin and eosin staining of adipocytes (A–D; magnification ×10; scale bar = 400 µm); haematoxylin and eosin staining of left ventricle indicating inflammatory cells as dark spots outside myocytes and in vascular endothelium marked as arrow (E–H; magnification ×20; scale bar = 200 µm); and picrosirius red staining of left ventricle indicating collagen deposition as red stain marked by arrows (I–L; magnification ×12.6; scale bar = 100 µm). Corn starch diet-fed rats (A,E,I), corn starch diet-fed rats treated with Garcinia dulcis rind powder (B,F,J), high-carbohydrate, high-fat diet-fed rats (C,G,K) and high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder (D,H,L).
Figure 4Haematoxylin and eosin staining of liver indicating inflammatory cells as dark spots marked by arrow and fat vacuoles marked as “f”) (A–D; magnification ×20; scale bar = 200 µm); picrosirius red staining of liver indicating collagen deposition as red stain around blood vessels marked by arrows (E–H; magnification ×12.6; scale bar = 100 µm); and oil red O stain of liver showing fat droplets in red (I–L; magnification ×12.6; scale bar = 200 µm). Corn starch diet-fed rats (A,E,I), corn starch diet-fed rats treated with Garcinia dulcis rind powder (B,F,J), high-carbohydrate, high-fat diet-fed rats (C,G,K) and high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder (D,H,L).
Figure 5Haematoxylin and eosin staining of ileum (A–D) and colon (E–H; magnification ×20; scale bar = 200 µm) in corn starch diet-fed rats (A,E), corn starch diet-fed rats treated with Garcinia dulcis rind powder (B,F), high-carbohydrate, high-fat diet-fed rats (C,G) and high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder (D,H).
Figure 6Rarefaction curves (A) before and (B) after normalisation (14,908 sequences).
Figure 7Shannon diversity (A) and richness (B) of faecal samples. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder.
Figure 8Non-metric, multi-dimensional scaling (nMDS) plot of bacterial community structure of faecal samples from C, CGD, H and HGD rats. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder.
PERMANOVAs based on Bray–Curtis similarity measure for square-root transformed abundances of all rat faecal samples.
|
|
|
|
|
|
|
|
| Diet | 1 | 6986.2 | 6986.2 | 7.0877 | 0.0001 | 9879 |
| Treatment | 1 | 7162.9 | 7162.9 | 7.267 | 0.0001 | 9905 |
| Diet × treatment | 1 | 2735.8 | 2735.8 | 2.7756 | 0.0001 | 9859 |
| Res | 18 | 17,742 | 985.68 | |||
| Total | 21 | 34,411 | ||||
|
| ||||||
|
|
|
|
| |||
| C, CGD | 2.2169 | 0.0019 | 462 | |||
| C, H | 2.6651 | 0.0074 | 126 | |||
| C, HGD | 2.2135 | 0.0026 | 462 | |||
| CGD, H | 3.2027 | 0.0017 | 462 | |||
| CGD, HGD | 1.7959 | 0.0018 | 461 | |||
| H, HGD | 2.2624 | 0.0024 | 461 | |||
|
| ||||||
|
|
|
| ||||
| C, CGD | 0.28079 | 0.8116 | ||||
| C, H | 1.6414 | 0.2101 | ||||
| C, HGD | 1.6237 | 0.2481 | ||||
| CGD, H | 2.4479 | 0.074 | ||||
| CGD, HGD | 1.7921 | 0.1642 | ||||
| H, HGD | 2.7484 | 0.0338 | ||||
p values were calculated using 9999 permutations under a residual model. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder.
Figure 9Effect of supplementation of diet (C or H) with Garcinia dulcis rind powder on the ratio of Firmicutes and Bacteroidetes (F/B) abundances in rat faecal samples. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder. A one-way ANOVA was performed, significant differences were observed between H samples and the other treatments (C, CGD and HGD; p < 0.0001, ****).
Figure 10Taxonomic profiles of bacterial communities shown at the class level. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder.
Figure 11Taxonomic profiles of bacterial communities shown at the family level. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder.
Figure 12Taxonomic profiles of bacterial communities shown at the genus level. C, corn starch diet-fed rats; CGD, corn starch diet-fed rats treated with Garcinia dulcis rind powder; H, high-carbohydrate, high-fat diet-fed rats; HGD, high-carbohydrate, high-fat diet-fed rats treated with Garcinia dulcis rind powder.
Summary of statistical tests on differential zOTU abundance.
|
| ||
| Diet | ||
| Treatment | ||
| Diet × Treatment | ||
|
| ||
|
|
|
|
| Diet | 19 | 1.70% |
| Treatment | 35 | 3.14% |
| Diet × Treatment | 2 | 0.18% |
| Total (unique zOTUs affected by one or more factors) | 56 | 5.03% |